Medical Gastroenterelogy Clinic Of the Prince Of Wales, Chinese University of Hong Kong
Shatin, Hong Kong
NCT Number: NCT03300804
The purpose of this study is to determine whether a 20- herb formulation, as a well characterised extract, is efficacious in treating irritable bowel syndrome (IBS) and also to identify efficacious and safe dosage of the formulation in treating IBS.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Shatin, Hong Kong
The Specific aims of the project are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
Placebo herb formulation
Time frame: 8 weeks
The primary endpoint for this study is the efficacy at the 8 week followup visit of the herbal formulations, which is defined by the patient's global assessment of the IBS symptoms.
Time frame: 8 weeks
The Bowel Symptom Scale will be used to assess changes in individual IBS and global IBS symptoms during the course of illness.
Time frame: 8 weeks
Quality of Life generic (SF-36), will be used for assessment of quality of life in response to treatment.
Time frame: 8 weeks
Disease-specific (IBS-QoL) will be used for assessment of quality of life in response to treatment.
University of Maryland, Baltimore
Other
Dose Escalation Trial Of Traditional Chinese Medicine For Irritable Bowel Syndrome
Acronym: TCM-IBS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06687720
Colonic Diseases, Colonic Diseases, Functional
Ahmedabad, Gujarat, India
View Trial DetailsNCT07722572
Anxiety Disorders, Colonic Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02136745
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT06268717
Abdominal Pain, Alpha-Gal Syndrome
Chapel Hill, North Carolina, United States
View Trial Details